Cytosine deaminase gene as a potential tool for the genetic therapy of colorectal cancer

Journal of Surgical Oncology

Volumn 61, Issue 1, 1996, Pages 42-48

  Rowley, Simon ^a   Lindauer, Marcus ^a   Gebert, Johannes F ^a,c   Haberkorn, Uwe ^b   Oberdorfer, Franz ^b   Moebius, Ulrich ^b   Herfarth, Christian ^a   Schackert, Hans Konrad ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

colorectal cancer; cytosine deaminase; in situ gene therapy

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL;

ADENOCARCINOMA; ARTICLE; CANCER CELL DESTRUCTION; COLORECTAL CANCER; CONTROLLED STUDY; ESCHERICHIA COLI; GENE THERAPY; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

BASE SEQUENCE; CELL DEATH; CLONING, MOLECULAR; COLORECTAL NEOPLASMS; CYTOSINE DEAMINASE; ESCHERICHIA COLI; FLUCYTOSINE; FLUOROURACIL; GENE THERAPY; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; INTERLEUKIN-2; MOLECULAR SEQUENCE DATA; NUCLEOSIDE DEAMINASES; POLYMERASE CHAIN REACTION; R FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0030052275     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199601)61:1<42::AID-JSO10>3.0.CO;2-Z     Document Type: Article

References (33)

1. Boring CC, Squires TS, Tong T: Cancer statistics 1993. CA 43:7-26, 1993.
2. Morrow CE, Grage TB, Sutherland DER, Najarian JS: Hepatic resection for secondary neoplasms. Surgery 92:610-614, 1982.
3. Holm A, Bradley E, Aldrete JS: Hepatic resection of metastases from colorectal carcinoma: Morbidity, mortality, and pattern of recurrence. Ann Surg 209:428-434, 1989.
4. Scheele J, Stangl R, Altendorf-Hofmann A: Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. Br J Surg 77:1241-1246, 1990.
5. Doci R, Gennari L, Bignami P, et al.: One hundred patients with hepatic metastases from colorectal cancer treated by resection: Analysis of prognostic determinants. Br J Surg 78:797-801, 1991.
6. Cortesi E, Padovani A, Aloe A, et al.: Advanced colorectal cancer: Impact of chemotherapy on survival. J Surg Oncol (Suppl 2):112-115, 1991.
7. Rosenberg SA, Anderson WF, Blaese RM, et al.: Immunization of cancer patients using autologous cancer cells modified by the insertion of the gene for interleukin-2. Hum Gene Ther 3:75-90, 1992.
8. Moolten FL: Tumor chemosensitivity conferred by inserted Herpes Thymidine Kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46:5276-5281, 1986.
9. Danielsen S, Kilstrup M, Barilla K, et al.: Characterization of the Escherichia coli codBA operon encoding cytosine permease and cytosine deaminase. Mol Microbiol 6:1335-1344, 1992.
10. Austin EA, Huber BE: A first step in the development of gene therapy for colorectal carcinoma: Cloning, sequencing, and expressing of Escherichia coli cystosine deaminase. Mol Pharmacol 43:380-387, 1993.
11. Mullen CA, Kilstrup M, Blaese RM: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system. Proc Natl Acad Sci USA 89:33-37, 1992.
12. Huber BE, Austin EA, Good SS, et al.: In vivo antitumour activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 53:4619-4626, 1993.
13. Mullen CA, Coale MM, Lowe R, Blaese RM: Tumors expressing the cylosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res 54:1503-1506, 1994.
14. Kozak M: Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 44:283-292, 1986.
15. Chaudhury AM, Smith GR: A new class of Escherichia coli recBC mutants: Implications for the role of RecBC enzyme in homologous recombination. Proc Natl Acad Sci USA 81:7850-7854, 1984.
16. Sanger F, Coulson AR: A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol 94:441-448, 1975.
17. Deuschle U, Pepperkok R, Wang F, et al.: Regulated expression of foreign genes in mammalian cells under the control of coliphage T3 RNA and lac repressor. Proc Natl Acad Sci USA 86:5400-5404, 1989.
18. Morikawa K, Walker SM, Jessup JM, Fidler IJ: In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res 48:1943-1948, 1988.
19. Grun BR, Berger U, Oberdorfer F, et al.: Metabolism and actions of 2-deoxy-2-D-galactose in vivo. Eur J Biochem 190:11-19, 1990.
20. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63, 1983.
21. Huber BE, Austin EA, Richards CA, et al.: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91:8302-8306, 1994.
22. "The Pharmaceutical Codex, 11th ed." London: The Pharmaceutical Press, 1979.
23. Plagemann PGW, Woffendin C, Puziss MB, Wohlheuter RM: Purine and pyrimidine transport and permeation in human erythrocytes. Biochim Biophys Acta 905:17-29, 1987.
24. West TP, Shanley MS, O'Donovan GA: Purification and some properties of cytosine deaminase from Salmonella typhimurium. Biochim Biophys Acta 719:251-258, 1982.
25. Culver KW, Ram Z, Wallbridge S, et al.: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256:1550-152, 1992.
26. Oldfield EH, Culver KW, Ram Z, et al.: A clinical protocol: Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous gancyclovir. Hum Gene Ther 4:39-69, 1993.
27. Lotze MT, Matory YL, Rayner AA, et al.: Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58:2764-2772, 1986.
28. Huland E, Huland H: Local continuous high dose interleukin-2: A new therapeutic model for the treatment of advanced bladder cancer. Cancer Res 49:1-6, 1989.
29. Eggermont AM, Goey SH, Bolhuis RL, Stoter G: Regional application of cytokine: Experience with various clinical protocols. Pharmacol Res 26:54-55, 1992.
30. Reid I, Sharpe I, Maxwell W, et al.: A phase 2 trial of recombinant interleukin-2 and 5-fluorouracil in patients with metastatic colorectal carcinoma. Eur J Surg Oncol 18:591-598, 1992.
31. Hamblin TJ, Sadhullah S, Williamson P, et al : A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer. Br J Cancer 68:1186-1189, 1993.
32. Hiddeman W, Ruelfs C, Ottensmeier L, et al.: Interleukin-2 followed by fluorouracil and folinic acid in refractory colorectal cancer - Results of a clinical phase II study. Semin Oncol 19:225-227, 1992.
33. Rosenberg SA, Lotze MT, Muul LM, et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316:889-897, 1987.